The prognosis of patients with recurrent breast cancer also improved over time after the introduction of aromatase inhibitors and trastuzumab, and the survival improvement was especially apparent in patients with ER-positive and/or HER2-positive tumors. This evidence concerns the gene ERBB2 and breast cancer.